Epigen to license its LPA1 Receptor small molecule program to Novo Nordisk
Epigen Biosciences announced that it has entered into a collaboration agreement with Novo Nordisk A/S under which Novo Nordisk has licensed the LPA1 receptor antagonist EPGN696 for…
Read More...
Read More...